

EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

Estado
EC Finalizado

Tipo de Participantes
No aportado

Rangos de Edad
Mayores de 64

Género
Ambos

Fases
Fase II

Participantes esperados
38

Resultados
Sin resultados

Bajo nivel intervención
No

Enfermedad rara
Si

Cobertura geográfica
Sin determinar

Ámbitos del ensayo
seguridad, eficacia, farmacocinética

Terapia avanzada
NO

Información

Identificador
2023-504832-16-00 (CTIS)

Cod. Protocolo
No aportado

Transicionado 2021-005744-29

Área terapéutica
Enfermedades [C] - Cáncer [C04]

Enfermedad investigada
DIFFUSE LARGE B CELL LYMPHOMA

Título Científico
A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Evaluate the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) as Monotherapy or in Combination with Lenalidomide as First-Line Therapy for Anthracycline-Ineligible Subjects with Diffuse Large B-Cell Lymphoma

Justificación

No aportado

Objetivo Principal

Evaluate the clinical efficacy of epcoritamab monotherapy or epcoritamab and lenalidomide

Variables de Evaluación Primaria

Complete response (CR) rate determined by Lugano criteria

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Evaluate other efficacy measures of epcoritamab monotherapy or epcoritamab and lenalidomide
Evaluate safety and tolerability of epcoritamab monotherapy or epcoritamab and lenalidomide
Evaluate immunogenicity
Assess the pharmacokinetics of epcoritamab
Evaluate patient-reported outcomes related to lymphoma symptoms

Variables de Evaluación Secundaria

Duration of response (DOR) determined by Lugano criteria
Duration of complete response (DOCR) determined by Lugano criteria
Time to response (TTR) determined by Lugano criteria
Overall response rate (ORR) determined by Lugano criteria
Progression-free survival (PFS) determined by Lugano criteria
Time to next (anti-lymphoma) therapy (TTNT).
Rate and duration of minimal residual disease (MRD) negative status
Overall survival (OS)
Incidence of dose-limiting toxicities (DLTs)
Incidence and severity of adverse events (AEs)
Incidence and severity of changes in laboratory values
Incidence of antidrug antibodies (ADAs) to epcoritamab
PK parameters (clearance, volume of distribution, area under-the- concentration-time curve [AUC_{0-last} and AUC_{0-∞}], maximum concentration [C_{max}], time of C_{max} [T_{max}], predose values, and half-life [t_{1/2}])
Changes in lymphoma symptoms as measured by the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym)

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Must have newly diagnosed CD20+ large cell lymphoma.

Is ineligible for anthracycline-based therapy/cytotoxic chemotherapy due to: oBeing age 80 years; AND/OR oBeing age 75 years and having important comorbid condition(s), which are likely to have a negative impact on tolerability of anthracycline-based therapy/cytotoxic chemotherapy, Have Immune Effector Cell-Associated Encephalopathy (ICE) score of at least 8 out of 10.

Have Ann Arbor Stage II-IV disease.

Have ECOG PS of 0, 1, or 2; (ECOG PS of 3 may be considered if impairment is attributed to current lymphoma/DLBCL and if pre-phase treatment during the screening phase results in an improvement of ECOG PS to 2 prior to enrollment.)

Have measurable disease as per Lugano criteria.

Have acceptable organ function based on baseline bloodwork.

Must have fresh (preferred) or archival biopsy material at screening.

Criterios de Exclusión

Has known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection at trial enrollment, including COVID-19 infection.

Has suspected active or inadequately treated latent tuberculosis.

Has a known history of seropositivity for HIV. Note: HIV testing is required at screening only if required per local health authorities or institutional standards.

Has severe cardiovascular disease (other than those eligibility criteria that preclude the subject from receiving anthracycline-based therapy/cytotoxic chemotherapy).

Has been exposed to/received any of the following prior therapies, treatments, or procedures within the specified timeframes: oMajor surgery within 4 weeks prior to the first dose of epcoritamab; oNon-investigational antineoplastic agents or any investigational drug within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of epcoritamab; oAutologous hematopoietic stem cell transplantation (HSCT), CAR-T, allogeneic stem cell transplantation, or solid organ transplantation; oLive, attenuated vaccines within 30 days prior to initiation of epcoritamab; oInvestigational vaccines within 28 days before the planned first dose of epcoritamab (ie, experimental and/or non-authorized SARS-CoV-2 vaccinations and therapies are not allowed); oInvasive investigational medical device use within 28 days before the planned first dose of epcoritamab.

Has primary central nervous system (CNS) tumor or known CNS involvement or intracranial involvement as confirmed by mandatory brain magnetic resonance imaging/computed tomography (MRI/CT) scan at screening and, if clinically indicated, by lumbar puncture.

Has a seizure disorder requiring anti-epileptic therapy or experienced a seizure within 6 months of signing an informed consent form.

Has known past or current malignancy other than inclusion diagnosis, with exceptions as stated in protocol.

Has known or suspected allergies, hypersensitivity, or intolerance to either of the trial treatments or has known or suspected contraindication to the use of all locally available anti-cytokine therapies per local guidelines for management of cytokine release syndrome (CRS).

Has active hepatitis B virus (HBV) (DNA polymerase chain reaction [PCR]-positive) or hepatitis C virus (HCV) (RNA PCR-positive) infection, current alcohol abuse, or cirrhosis.

Has active cytomegalovirus (CMV) infection (DNA PCR-positive) requiring treatment.

Calendario

(Última actualización: 16/06/2026)

Autorización 24/10/2022	Inicio de Ensayo 24/01/2023	Inclusión Primer Paciente 05/05/2023	Interrumpido No aportado	Reiniciado No aportado
Fin de reclutamiento 14/05/2025	Fin prematuro (España) 01/06/2026	Fin prematuro (Global) No aportado	Fin del ensayo en España No aportado	Fin del ensayo global 10/06/2026

Promotor

Genmab A/S Denmark

Kalvebod Brygge 43

Contact Person

Information

+4570202728

clinicaltrials@genmab.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital General Universitario Gregorio Marañón

C/ Doctor Esquerdo, 46 28007 Madrid

ceim.hgugm@salud.madrid.org

915867007

Centros

Activo (26/06/2023)	Complejo Hospitalario Gregorio Marañón	Madrid	MADRID	
Activo (18/08/2023)	HOSPITAL CLINIC DE BARCELONA	Barcelona	BARCELONA	
No iniciado (---/---/----)	Hospital General Universitario Gregorio Marañón	Madrid	MADRID	Haematology
Activo (19/07/2023)	HOSPITAL SAN PEDRO DE ALCANTARA	Cáceres	CÁCERES	
No iniciado (---/---/----)	Hospital San Pedro De Alcantara	Caceres	CÁCERES	Haematology
Activo (24/10/2023)	HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA	Badalona	BARCELONA	
Activo (18/04/2023)	HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ	Madrid	MADRID	
Activo (28/02/2023)	HOSPITAL UNIVERSITARIO PUERTA DEL MAR	Cádiz	CÁDIZ	

Activo (31/01/2023)

HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Madrid

MADRID

No iniciado (---/---/----)

Hospital Universitario Virgen De La Macarena

Sevilla

SEVILLA

Hematology

Activo (14/06/2023)

HOSPITAL UNIVERSITARIO VIRGEN DE VALME

Sevilla

SEVILLA

Activo (20/04/2023)

HOSPITAL UNIVERSITARIO VIRGEN MACARENA

Sevilla

SEVILLA

Activo (31/01/2023)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

No iniciado (---/---/----)

Institut Catala D'oncologia

Badalona

BARCELONA

Oncology

No iniciado (---/---/----)

Institut Catala D'oncologia

L'hospitalet De Llobregat

BARCELONA

Haematology

No iniciado (---/---/----)

Institut Catala D'oncologia

Badalona

BARCELONA

Oncology

Activo (14/08/2023)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Medicamentos

-
-
SUBCUTANEOUS

Código ATC: L04AC03 - ANAKINRA
Principios Activos: N/A
Experimental

-
-
INTRAVENOUS

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A
Experimental

-
-
INTRAVENOUS

Código ATC: L04AC07 - TOCILIZUMAB
Principios Activos: N/A
Experimental

-
-
INTRAVENOUS

Código ATC: R06AA02 - DIFENHIDRAMINA
Principios Activos: N/A
Experimental

-
-
ORAL



Código ATC: N02BE01 - PARACETAMOL
Principios Activos: N/A
Experimental

-
-
INTRAVENOUS

Código ATC: L04AC11 - SILTUXIMAB
Principios Activos: N/A
Experimental

Epcoritamab
SOLUTION FOR INJECTION
SUBCUTANEOUS
-
Principios Activos: N/A
Huérfano
Experimental

-
-
ORAL
Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A
Experimental



Epcoritamab

SOLUTION FOR INJECTION

SUBCUTANEOUS

Principios Activos: N/A

Huérfano

Experimental

Sin resultados

EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

State
Finished CT

Type of participants
Not provided

Age Ranges
Older than 64

Gender
Both

Phases
Phase II

Expected Participants
38

Results
No results

Low level of intervention
No

Rare disease
Yes

Geographic coverage
Undetermined

Areas of the study
safety, effectiveness, pharmacokinetics

Advanced therapy
NO

Information

Identifier
2023-504832-16-00 (CTIS)

Protocol Code
No aportado

Transitioned 2021-005744-29

Therapeutic area
Diseases [C] - Cancer [C04]

Investigated Disease
DIFFUSE LARGE B CELL LYMPHOMA

Scientific Title
A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Evaluate the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) as Monotherapy or in Combination with Lenalidomide as First-Line Therapy for Anthracycline-Ineligible Subjects with Diffuse Large B-Cell Lymphoma

Rationale

Not provided

Main Objective

Evaluate the clinical efficacy of epcoritamab monotherapy or epcoritamab and lenalidomide

Primary Endpoints

Complete response (CR) rate determined by Lugano criteria

Temporary moments of secondary assessment

Not provided

Secondary Objective

Evaluate other efficacy measures of epcoritamab monotherapy or epcoritamab and lenalidomide
Evaluate safety and tolerability of epcoritamab monotherapy or epcoritamab and lenalidomide
Evaluate immunogenicity
Assess the pharmacokinetics of epcoritamab
Evaluate patient-reported outcomes related to lymphoma symptoms

Secondary Endpoints

Duration of response (DOR) determined by Lugano criteria
Duration of complete response (DOCR) determined by Lugano criteria
Time to response (TTR) determined by Lugano criteria
Overall response rate (ORR) determined by Lugano criteria
Progression-free survival (PFS) determined by Lugano criteria
Time to next (anti-lymphoma) therapy (TTNT).
Rate and duration of minimal residual disease (MRD) negative status
Overall survival (OS)
Incidence of dose-limiting toxicities (DLTs)
Incidence and severity of adverse events (AEs)
Incidence and severity of changes in laboratory values
Incidence of antidrug antibodies (ADAs) to epcoritamab
PK parameters (clearance, volume of distribution, area under-the- concentration-time curve [AUC_{0-last} and AUC_{0-∞}], maximum concentration [C_{max}], time of C_{max} [T_{max}], predose values, and half-life [t_{1/2}])
Changes in lymphoma symptoms as measured by the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym)

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Must have newly diagnosed CD20+ large cell lymphoma.

Is ineligible for anthracycline-based therapy/cytotoxic chemotherapy due to: oBeing age 80 years; AND/OR oBeing age 75 years and having important comorbid condition(s), which are likely to have a negative impact on tolerability of anthracycline-based therapy/cytotoxic chemotherapy, Have Immune Effector Cell-Associated Encephalopathy (ICE) score of at least 8 out of 10.

Have Ann Arbor Stage II-IV disease.

Have ECOG PS of 0, 1, or 2; (ECOG PS of 3 may be considered if impairment is attributed to current lymphoma/DLBCL and if pre-phase treatment during the screening phase results in an improvement of ECOG PS to 2 prior to enrollment.)

Have measurable disease as per Lugano criteria.

Have acceptable organ function based on baseline bloodwork.

Must have fresh (preferred) or archival biopsy material at screening.

Exclusion criteria

Has known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection at trial enrollment, including COVID-19 infection.

Has suspected active or inadequately treated latent tuberculosis.

Has a known history of seropositivity for HIV. Note: HIV testing is required at screening only if required per local health authorities or institutional standards.

Has severe cardiovascular disease (other than those eligibility criteria that preclude the subject from receiving anthracycline-based therapy/cytotoxic chemotherapy).

Has been exposed to/received any of the following prior therapies, treatments, or procedures within the specified timeframes: oMajor surgery within 4 weeks prior to the first dose of epcoritamab; oNon-investigational antineoplastic agents or any investigational drug within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of epcoritamab; oAutologous hematopoietic stem cell transplantation (HSCT), CAR-T, allogeneic stem cell transplantation, or solid organ transplantation; oLive, attenuated vaccines within 30 days prior to initiation of epcoritamab; oInvestigational vaccines within 28 days before the planned first dose of epcoritamab (ie, experimental and/or non-authorized SARS-CoV-2 vaccinations and therapies are not allowed); oInvasive investigational medical device use within 28 days before the planned first dose of epcoritamab.

Has primary central nervous system (CNS) tumor or known CNS involvement or intracranial involvement as confirmed by mandatory brain magnetic resonance imaging/computed tomography (MRI/CT) scan at screening and, if clinically indicated, by lumbar puncture.

Has a seizure disorder requiring anti-epileptic therapy or experienced a seizure within 6 months of signing an informed consent form.

Has known past or current malignancy other than inclusion diagnosis, with exceptions as stated in protocol.

Has known or suspected allergies, hypersensitivity, or intolerance to either of the trial treatments or has known or suspected contraindication to the use of all locally available anti-cytokine therapies per local guidelines for management of cytokine release syndrome (CRS).

Has active hepatitis B virus (HBV) (DNA polymerase chain reaction [PCR]-positive) or hepatitis C virus (HCV) (RNA PCR-positive) infection, current alcohol abuse, or cirrhosis.

Has active cytomegalovirus (CMV) infection (DNA PCR-positive) requiring treatment.

Calendar

(Last Update: 16/06/2026)

Authorization 24/10/2022	Start of Trial 24/01/2023	First patient inclusion 05/05/2023	Halted Not aported	Restarted Not aported
-----------------------------	------------------------------	--	-----------------------	--------------------------

End of recruitment 14/05/2025	Premature end (Spain) 01/06/2026	Premature End (Global) Not aported	Trial end (Spain) Not aported	Trial end (Global) 10/06/2026
-------------------------------------	--	--	-------------------------------------	-------------------------------------

Sponsor

Genmab A/S Denmark

Kalvebod Brygge 43

Contact Person

Information

+4570202728

clinicaltrials@genmab.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital General Universitario Gregorio Marañón

C/ Doctor Esquerdo, 46 28007 Madrid

ceim.hgugm@salud.madrid.org

915867007

Sites

Active (26/06/2023)	Complejo Hospitalario Gregorio Marañón Madrid MADRID
Active (18/08/2023)	HOSPITAL CLINIC DE BARCELONA Barcelona BARCELONA
not initialized (---/---/----)	Hospital General Universitario Gregorio Marañón Madrid MADRID Haematology
Active (19/07/2023)	HOSPITAL SAN PEDRO DE ALCANTARA Cáceres CÁCERES
not initialized (---/---/----)	Hospital San Pedro De Alcantara Caceres CÁCERES Haematology
Active (24/10/2023)	HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA Badalona BARCELONA
Active (18/04/2023)	HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ Madrid MADRID
Active (28/02/2023)	HOSPITAL UNIVERSITARIO PUERTA DEL MAR Cádiz CÁDIZ

Active (31/01/2023)

HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Madrid

MADRID

not initialized (---/---/----)

Hospital Universitario Virgen De La Macarena

Sevilla

SEVILLA

Hematology

Active (14/06/2023)

HOSPITAL UNIVERSITARIO VIRGEN DE VALME

Sevilla

SEVILLA

Active (20/04/2023)

HOSPITAL UNIVERSITARIO VIRGEN MACARENA

Sevilla

SEVILLA

Active (31/01/2023)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

not initialized (---/---/----)

Institut Catala D'oncologia

Badalona

BARCELONA

Oncology

not initialized (---/---/----)

Institut Catala D'oncologia

L'hospitalet De Llobregat

BARCELONA

Haematology

not initialized (---/---/----)

Institut Catala D'oncologia

Badalona

BARCELONA

Oncology

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Active (14/08/2023)

Medication

-
-
SUBCUTANEOUS

ATC code: L04AC03 - ANAKINRA
Active Principles: N/A
Experimental

-
-
INTRAVENOUS

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A
Experimental

-
-
INTRAVENOUS

ATC code: L04AC07 - TOCILIZUMAB
Active Principles: N/A
Experimental

-
-
INTRAVENOUS

ATC code: R06AA02 - DIFENHIDRAMINA
Active Principles: N/A
Experimental

-
-
ORAL

ATC code: N02BE01 - PARACETAMOL
Active Principles: N/A
Experimental



-
-
INTRAVENOUS

ATC code: L04AC11 - SILTUXIMAB
Active Principles: N/A
Experimental

Epcoritamab
SOLUTION FOR INJECTION
SUBCUTANEOUS
-
Active Principles: N/A
Orphan
Experimental

-
-
ORAL

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A
Experimental



Epcoritamab
SOLUTION FOR INJECTION
SUBCUTANEOUS

—

Active Principles: N/A

Orphan

Experimental

No results